CD274 and small cell lung carcinoma: The CAPSTONE-1 and ASTRUM-005 phase 3 trials also yielded positive results using different PD‐L1 (adebrelimab) and PD-1 (serplulimab) inhibitors, respectively, and these two drugs were approved by the National Medical Products Administration (NMPA) for first-line treatment of ES-SCLC [237, 238].